Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTZPY6J)

• DTT Name: Tyrosine-protein kinase UFO (AXL) DTT Info
• Gene Name: AXL

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[1]

15 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bemcentinib	DM0YCPL	Myelodysplastic syndrome	2A37	Phase 2	[2]
BGB-324	DMDI43Y	Breast cancer	2C60-2C65	Phase 2	[3]
BI-505	DMSZQHX	Multiple myeloma	2A83	Phase 2	[4]
Mecbotamab vedotin	DMU5KH4	Ovarian cancer	2C73	Phase 2	[5]
MGCD265	DMRPCF2	Non-small-cell lung cancer	2C25.Y	Phase 2	[6]
Enapotamab vedotin	DM1PQJO	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[1]
TP-0903	DMHTG8P	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[1]
A416	DMBQXAX	Aggressive cancer	2A00-2F9Z	Phase 1	[8]
AVB-S6-500	DMKCRMD	Acute myeloid leukaemia	2A60	Phase 1	[1]
BPI-9016 M	DMNY0U5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
DS-1205	DMXST9F	Non-small-cell lung cancer	2C25.Y	Phase 1	[1]
INCB81776	DMFOXGB	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
PF-07265807	DMSMNRQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
RXDX-106	DM6NVTR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

4 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cu-anti-hAXL	DMKVW25	Breast cancer	2C60-2C65	Preclinical	[13]
DP-3975	DMYH3VR	Mesothelioma	2C51.2	Preclinical	[14]
GL21.T	DMZC91G	Non-small-cell lung cancer	2C25.Y	Preclinical	[14]
YW327.6S2	DMH0I9N	Breast cancer	2C60-2C65	Preclinical	[14]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LDC1267	DMH7R6L	Discovery agent	N.A.	Investigative	[15]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835).
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of BioAtla
• [6] Company report (Mirati Therapeutics: formerly MethylGene)
• [7] Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.
• [8] Clinical pipeline report, company report or official report of Klus Pharma
• [9] First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.
• [10] A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
• [11] National Cancer Institute Drug Dictionary (drug name PF-07265807).
• [12] National Cancer Institute Drug Dictionary (drug name RXDX106).
• [13] MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer. Contrast Media Mol Imaging. 2017 May 14;2017:1686525.
• [14] AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
• [15] The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12.